<DOC>
	<DOCNO>NCT00001534</DOCNO>
	<brief_summary>The human heart divide four chamber . One four chamber , leave ventricle , chamber mainly responsible pump blood heart circulation . Hypertrophic cardiomyopathy ( HCM ) genetically inherit disease cause abnormal thicken heart muscle , especially muscle making leave ventricle . When left ventricle become abnormally large call leave ventricular hypertrophy ( LVH ) . This condition cause symptom chest pain , shortness breath , fatigue , heart beat palpitation . This study design compare ability two drug ( enalapril losartan ) improve symptom heart function patient diagnose hypertrophic cardiomyopathy ( HCM ) . Researchers decide compare drug one use treat patient diseases cause thicken heart muscle . In condition , enalapril losartan improve symptom , decrease thickness heart muscle , improve blood flow supply heart muscle , improve pump action heart muscle . In study researcher compare effectiveness enalapril losartan give separately together patient hypertrophic cardiomyopathy ( HCM ) .</brief_summary>
	<brief_title>Long Term Effects Enalapril Losartan Genetic Heart Disease</brief_title>
	<detailed_description>Hypertrophic cardiomyopathy ( HCM ) genetic cardiac disease characterize left ventricular ( LV ) hypertrophy . There often associate LV diastolic dysfunction myocardial ischemia . The severity LV hypertrophy , diastolic dysfunction , myocardial ischemia important determinant clinical outcome . Angiotensin II modulate cell growth cardiac function . There also increase evidence renin-angiotensin system ( RAS ) may present cardiac cell , hypertrophic action angiotensin II could therefore mediate circulate locally produce hormone . Animal clinical study demonstrate independent effect systemic blood pressure , ACE inhibition angiotensin II receptor ( AT1 ) blockade reduce cardiac hypertrophy , improve LV diastolic function myocardial ischemia . AT1 blockade may preferable ACE inhibitor inhibit angiotensin II binding receptor , system turn irrespective source angiotensin II . Also , may fewer side effect due lack bradykinin . This double-blind , placebo-controlled study examines ability enalapril ( ACE inhibition ) losartan ( AT1 blockade ) , separately combination , cause regression cardiac hypertrophy , improve LV function myocardial perfusion non-obstructive HCM .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>INCLUSION CRITERIA HCM either gender , age 2055 year . Nondilated LV ( LVIDd le 60 mm ) LV wall thickness great equal 16 mm measure LV segment NMR . Nonobstructive HCM : A LV outflow gradient less equal 30 mm Hg gradient rest less equal 55 mm Hg follow isoproterenol infusion heart rate great equal 120 beat per minute cardiac catheterization . New York Heart Association functional class IIII . Patients participate previous toxicity study may recruit study , wish . Patients previously take ACE inhibitor losartan could include study , drug period 6 month longer . EXCLUSION CRITERIA Severe cardiac symptom rest ( NYHA IV ) . LV outflow tract gradient great 30 mm Hg rest great 55 mm Hg follow isoproterenol infusion heart rate great equal 120 beat per minute cardiac catheterization . Systemic disease ( respiratory , neurologic , locomotor ) prevent exercise testing , echocardiography NMR , MUGA , thallium study , cardiac catheterization . Coronary artery disease ( great 50 % arterial luminal narrowing major epicardial vessel ) congenital cardiovascular abnormality ( e.g . ASD , VSD , coronary anomaly ) . Chronic atrial fibrillation . Bleeding disorder ( PTT great 35 sec , pro time great 14.7 sec , platelet count le 154 k/mm3 ) . Anemia ( Hb le 12.7 g/dl male less 11.0 g/dl female ) ; renal impairment ( BUN great 22 mg/dl serum creatinine great 1.4 mg/dl ) ; K+ le 3.3 mmol/l great 5.1 mmol/l . Hypertension : basal systolic diastolic pressure great 160 mm Hg great 95 mm Hg , respectively two occasion separate one hour rest . Hypotension : basal sit systolic arterial pressure le 100 mm Hg confirm 30 minute later . Must ability estimate LV wall thickness . Radiographic evidence overt cardiac failure ( pulmonary edema chest Xray ) . Negative urine pregnancy test . Pregnant lactate female patient . Diminished LV systolic function ( rest exercise LV ejection fraction estimate radionuclide angiography less 50 % ) . Dependence cardioactive drug diuretic , verapamil , Bblockers , antiarrhythmic drug control symptoms arrhythmias . Negative HIV test . Sensitivity ACE inhibitor e.g . angioedema . Must ability set outpatient monitoring system .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>Genetics</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Diastolic Dysfunction</keyword>
	<keyword>Renin-Angiotensin System</keyword>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
	<keyword>Left Ventricular ( LV ) Hypertrophy</keyword>
</DOC>